ORION Corp. (KRX:271560)
South Korea · Delayed Price · Currency is KRW 127,600
-2,100 (-1.62%)
Last updated: Sep 2, 2026, 2:20 PM KST
ORION Revenue
ORION had revenue of 893.59B KRW in the quarter ending June 30, 2026, with 14.98% growth. This brings the company's revenue in the last twelve months to 3.58T, up 11.25% year-over-year. In the year 2025, ORION had annual revenue of 3.33T with 7.35% growth.
Revenue (ttm)
3.58T
Revenue Growth
+11.25%
P/S Ratio
1.43
Revenue / Employee
2.43B
Employees
1,471
Market Cap
5.13T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.33T | 228.10B | 7.35% |
| Dec 31, 2024 | 3.10T | 191.98B | 6.59% |
| Dec 31, 2023 | 2.91T | 39.11B | 1.36% |
| Dec 31, 2022 | 2.87T | 517.75B | 21.98% |
| Dec 31, 2021 | 2.36T | 125.68B | 5.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CJ Cheiljedang | 28.39T |
| KT&G Corporation | 6.95T |
| LG H&H | 6.29T |
| Amorepacific | 4.49T |
| Nongshim | 3.64T |
| Kolmar Korea | 2.93T |
| Samyang Foods | 2.75T |
| Cosmax | 2.66T |
ORION News
- 2 months ago - Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe - Business Upturn
- 2 months ago - Shilpa Medicare partners with Orion for nivolumab biosimilar development in Europe - Business Upturn
- 1 year ago - Orion Corporation's financial reporting and Annual General Meeting in 2026 - Benzinga
- 1 year ago - Shilpa Medicare subsidiary partners with Orion Corporation to commercialize Recombinant Human Albumin in Europe - Business Upturn